| Literature DB >> 32344524 |
Lorena Franco-Martínez1, Andrea Gelemanović2, Anita Horvatić3, María Dolores Contreras-Aguilar1, Roman Dąbrowski4, Vladimir Mrljak3, José Joaquín Cerón1, Silvia Martínez-Subiela1, Asta Tvarijonaviciute1.
Abstract
The aim of this study was to evaluate changes in serum and saliva proteomes in canine mammary tumors (CMT) using a high-throughput quantitative proteomic analysis in order to potentially discover possible biomarkers of this disease. Proteomes of paired serum and saliva samples from healthy controls (HC group, n = 5) and bitches with CMT (CMT group, n = 5) were analysed using a Tandem Mass Tags-based approach. Twenty-five dogs were used to validate serum albumin as a candidate biomarker in an independent sample set. The proteomic analysis quantified 379 and 730 proteins in serum and saliva, respectively. Of those, 35 proteins in serum and 49 in saliva were differentially represented. The verification of albumin in serum was in concordance with the proteomic data, showing lower levels in CMT when compared to the HC group. Some of the modulated proteins found in the present study such as haptoglobin or S100A4 have been related to CMT or human breast cancer previously, while others such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D are described here for the first time. Our results indicate that saliva and serum proteomes can reflect physiopathological changes that occur in CMT in dogs and can be a potential source of biomarkers of the disease.Entities:
Keywords: biomarker; cancer; canine mammary tumors; dog; proteomics; saliva; serum
Year: 2020 PMID: 32344524 DOI: 10.3390/ani10040741
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752